29.04.2024,
5130 Zeichen
London (ots/PRNewswire) - Huma Therapeutics ("Huma"), a leader in
global digital health innovation, together with Merck KGaA,
Darmstadt, Germany, a leading science and technology company, today
announced the launch of their innovative bladder cancer treatment
companion app in the United Kingdom. This collaboration underscores
Merck KGaA, Darmstadt, Germany and Huma's joint commitment to
advancing patient-directed care and empowering patients and
caregivers throughout their cancer care pathway.
The UK launch marks a significant milestone in the partnership
between Huma and Merck KGaA, Darmstadt, Germany, announced in
November 2023. Additional markets are planned for launch in the
coming year, and may support delivery of care for a range of cancers.
Enabling Better Care Experiences for Cancer Patients
The bladder cancer treatment companion app developed by Huma and
Merck KGaA, Darmstadt, Germany, is designed to support patients and
caregivers in navigating the complexities of bladder cancer treatment
by providing a reliable source of information and support throughout
the treatment journey. Built in collaboration with healthcare
professionals and leading patient organisations, the app aims to
provide patients with:
* Improved understanding of their treatment
* Better conversations with their care team
* Self-tracking of their health state
* Raising awareness of available holistic care services
* Encouraging connection with personal support network
* Expectation management and motivation through content
UK-based patient organisations and specialist cancer care centres
were involved in and piloting the bladder cancer treatment journey
app in advance of the launch.
Alex Filicevas, Executive Director at the World Bladder Cancer
Patient Coalition, emphasised the importance of the app in supporting
patients and caregivers through a complex treatment journey: "It was
a privilege to work alongside patients with bladder cancer and their
caregivers, helping to shape a new digital resource for patients with
bladder cancer to guide them through the complex path of treatment.
This initiative underscores our joint dedication to fostering patient
empowerment, shared decision-making and community within healthcare
delivery."
Joachim Chan, a consultant clinical oncologist at the Clatterbridge
Cancer Centre in Liverpool, noted the importance of patients being
well-informed: "Although there is a wealth of knowledge available to
patients through various websites, patients may understandably want a
reliable source of information through a single portal. Merck KGaA,
Darmstadt, Germany has collaborated with various stakeholders to
create an app to this end. This app will give clear informative
summaries of the treatment options available for patients and
relatives to absorb, so that they can approach treatment with a more
positive mindset, and by being well informed about the effects that
treatment may have on them, it would help facilitate them to continue
with their day-to-day living."
A Commitment to Advancing Patient Care
Dan Vahdat, Founder and CEO of Huma, said: "We are excited to launch
this innovative app in partnership with Merck KGaA, Darmstadt,
Germany, furthering our mission to transform healthcare with a
digital-first approach. By empowering patients with access to
personalised resources and support, we believe we can make a
meaningful difference in the lives of those affected by bladder
cancer."
Dr. Mert Aral, Chief Medical Officer at Huma, said: "This initiative
is designed to demystify the often overwhelming journey faced by
cancer patients. Our objective is clear – to improve patients'
understanding of their condition, enable smooth navigation through
complex care pathways, and promote consistent adherence to their
treatments. The UK debut marks the inception of our partnership's
endeavour to offer comprehensive guidance and unwavering support to
all individuals battling cancer."
About Huma
Huma Therapeutics is a global digital health technology company that
advances digital-first care delivery and research to help people live
longer, fuller lives. Its award-winning technology platform is used
by more than 3,000 hospitals and clinics, with over 1.8 million
active users in healthcare and over 700,000 participants across
research.
Huma's technology powers:
* virtual care tools ranging from digital-first screening and
population health initiatives to at-scale remote patient
monitoring (RPM)
* companion apps to support patients through treatment and drug
therapies
* digital clinical trials, including decentralised trials, to
accelerate medical research
Huma's regulated Software as a Medical Device (SaMD) platform is the
first disease- and device-agnostic platform to achieve EU MDR Class
IIb, US FDA 510(k) Class II and Saudi Class C regulatory clearance.
The SaMD platform is regulated to accept artificial intelligence
algorithms and monitor patients of all ages.
View original
content:https://www.prnewswire.co.uk/news-releases/huma-and-merck-kga
a-darmstadt-germany-launch-innovative-app-to-support-bladder-cancer-p
atients-302129830.html
Digital press kit:
http://www.ots.at/pressemappe/PR167548/aom
BSN Podcasts
Christian Drastil: Wiener Börse Plausch
Börsepeople im Podcast S12/19: Anna Wallner
Aktien auf dem Radar:FACC, Österreichische Post, Austriacard Holdings AG, Flughafen Wien, Amag, S Immo, OMV, Wienerberger, ATX Prime, ATX TR, Addiko Bank, Verbund, VIG, Rosgix, ams-Osram, AT&S, Pierer Mobility, RHI Magnesita, Oberbank AG Stamm, Agrana, CA Immo, Erste Group, EVN, Immofinanz, Kapsch TrafficCom, Telekom Austria, Uniqa, Wienerberger.
RWT AG
Die Firma RWT Hornegger & Thor GmbH wurde 1999 von den beiden Geschäftsführern Hannes Hornegger und Reinhard Thor gegründet. Seitdem ist das Unternehmen kontinuierlich, auf einen derzeitigen Stand von ca. 30 Mitarbeitern, gewachsen. Das Unternehmen ist in den Bereichen Werkzeugbau, Formenbau, Prototypenbau und Baugruppenfertigung tätig und stellt des Weiteren moderne Motorkomponenten und Präzisionsteile her.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER